Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 22;33:1289–1303. doi: 10.1007/s11095-016-1872-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2016

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 4 — The biodistribution of MET - lomustine nanomedicine formulations: a = plasma, b = brain, c = liver, d = bone (including bone marrow), ■ = MET – lomustine (13 mg kg⁻¹), □ MET - lomustine (6.5 mg kg⁻¹), ● = ethanolic lomustine (6.5 mg kg⁻¹). The MET formulation improves the delivery of lomustine to the brain by 2 fold by enabling a higher dose to be administered. Additionally, when compared to an ethanolic formulation of the drug at a dose of 6.5 mg kg⁻¹, the MET nanoparticles reduces the exposure (AUC_{0 – 4h}) of the bone marrow and liver to lomustine by 25 and 38% respectively, * = significant difference between the high dose MET formulation (13 mg kg⁻¹) and all other formulations (p < 0.05), # = significant difference between ethanolic formulation and both MET formulations (p < 0.05), § = significant difference between low dose MET formulation (6.5 mg kg⁻¹) and all other formulations (p < 0.05).